Reata Pharmaceuticals, Inc.
(NASDAQ : RETA)

( )
RETA PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Like Small Cap Stocks < $20?
You should, we just banked a 30% winner in 2 days!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson
-0.50%130.670.7%$876.22m
PFEPfizer Inc.
0.53%36.300.9%$660.82m
MRKMerck & Co., Inc.
0.40%84.680.7%$645.76m
ABBVAbbVie, Inc.
0.19%73.772.3%$552.14m
BMYBristol-Myers Squibb Company
-0.12%51.551.4%$505.04m
LLYEli Lilly and Company
-0.42%107.911.0%$305.36m
NVSNovartis AG Sponsored ADR
-0.77%85.930.2%$146.48m
AZNAstraZeneca PLC Sponsored ADR
0.60%43.841.2%$143.40m
GSKGlaxoSmithKline plc Sponsored ADR
-0.02%42.170.3%$93.41m
SNYSanofi Sponsored ADR
-0.13%44.890.2%$80.41m
NVONovo Nordisk A/S Sponsored ADR Class B
1.60%52.050.1%$71.85m
LCILannett Company, Inc.
-2.17%10.8235.6%$16.01m
AKTXAkari Therapeutics Plc Sponsored ADR
-1.65%1.791.6%$0.58m
EPIXESSA Pharma Inc
0.00%3.300.1%$0.09m

Company Profile

Reata Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. Its product candidates are bardoxolone methyl and omaveloxolone, which activate the transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation. The company was founded by J. Warren Huff on September 1, 2002 and is headquartered in Irving, TX.